In June 2025, French robotics company Wandercraft closed a Series D funding round of $75 million, according to reporting by The Robot Report. The capital injection is earmarked for three parallel tracks: bringing the Eve self-balancing personal exoskeleton to market, expanding clinical adoption of the Atalante X rehabilitation system, and developing and deploying a new humanoid robot called Calvin-40.
The funding round attracted participation from several investors, including Renault Group, the PSIM fund, Quadrant Management, and Teampact Ventures. Renault Group's involvement went beyond a simple financial contribution. The automaker acquired a minority stake in Wandercraft and entered a strategic partnership aimed at leveraging Renault's industrial manufacturing expertise to scale up production of Wandercraft's exoskeletons and robots.
Wandercraft described the funding as laying the groundwork for cost-efficient scaling of Eve and the broader Calvin humanoid family. The company also noted that Renault Group is its first commercial partner and the first customer for Calvin-40. The humanoid's name references its development timeline: Wandercraft claims the robot was developed in just 40 days using the company's rapid development process, integrated with NVIDIA's Isaac technologies.
The Series D announcement follows a period of significant growth for the company. Wandercraft reported a tenfold revenue increase since its last funding round, driven primarily by commercial expansion in the United States. The company's Atalante X rehabilitation system has received FDA clearance, which has supported its clinical adoption.
Wandercraft positions itself as a robotics company focused on restoring movement for people, industry, and humanity. The company's stated mission centers on putting movement at the heart of engineering innovation, leveraging artificial intelligence and real-world experience. Its flagship product, Eve, is described as the world's first self-balancing personal exoskeleton, designed to enable individuals with severe motor impairments to walk both indoors and outdoors.
The company also develops advanced robotics for rehabilitation and industrial applications, with a stated goal of restoring autonomy, dignity, and freedom of motion for users.
Why it matters for European robot service
The Wandercraft funding round carries particular significance for the European robotics ecosystem, and not only because the company is headquartered in France. The involvement of Renault Group as both an investor and a commercial partner signals a notable shift in how traditional European industrial manufacturers are engaging with robotics startups.
Renault's minority stake and strategic partnership represent a concrete example of an established European automotive manufacturer leveraging its industrial know-how to support robotics production at scale. This is not a passive investment. Renault is positioned as the first customer for Calvin-40, which means the automaker is not only helping Wandercraft build robots but is also committed to using them in its own operations. This dual role — investor, manufacturer partner, and customer — creates a vertically integrated relationship that could serve as a model for other European industrial companies looking to adopt robotics.
For the European robot service market, the implications are several. First, the partnership demonstrates a pathway for robotics companies to access large-scale manufacturing capabilities without building their own factories from scratch. Renault's industrial expertise in mass production, supply chain management, and quality control could help Wandercraft transition from producing relatively low volumes of medical exoskeletons to manufacturing humanoid robots at scale. This is a critical challenge for many European robotics companies, which often struggle to move beyond prototype and small-batch production.
Second, the funding round suggests that European investors and industrial partners are willing to commit substantial capital to robotics ventures. The $75 million Series D round, with contributions from multiple investors, indicates a level of confidence in the sector that could encourage other startups to pursue ambitious robotics programs. The participation of the PSIM fund, Quadrant Management, and Teampact Ventures, alongside Renault, shows a mix of financial and strategic investors.
Third, the development timeline for Calvin-40 — reportedly 40 days — raises questions about the pace of humanoid robot development in Europe. If Wandercraft's rapid development process, combined with NVIDIA's Isaac technologies, can produce functional humanoid robots in such a short timeframe, it could compress the innovation cycle for the entire sector. However, it is important to note that the source material does not specify what "developed" means in this context. The claim refers to development time, but the level of functionality, testing, and validation achieved in those 40 days is not disclosed.
The European context is also relevant because of the regulatory environment. Medical devices such as exoskeletons are subject to strict regulations in Europe, and the Atalante X's FDA clearance in the United States does not automatically translate to European regulatory approval. The source material does not specify the regulatory status of Atalante X in Europe, nor does it detail the regulatory pathway for Eve as a personal exoskeleton intended for home and outdoor use. These are open questions that buyers and operators will need to track.
The tenfold revenue increase reported by Wandercraft, driven by US commercial expansion, also raises questions about the European market. The source material does not break down revenue by region, so it is unclear how much of the company's growth is attributable to European sales versus US sales. For European buyers, this matters because it affects where Wandercraft is likely to focus its commercial efforts in the near term.
What buyers and operators should know
For healthcare institutions, rehabilitation centers, and industrial operators considering Wandercraft's products, the funding round provides some clarity about the company's trajectory, but several important details remain undisclosed.
On the rehabilitation side, Atalante X is Wandercraft's flagship system and has received FDA clearance. The company plans to expand clinical adoption of this system. For rehabilitation facilities, this suggests continued availability and potentially expanded support for the product. However, the source material does not specify the scope of the expansion, the target markets, or any changes to pricing, service, or support structures.
For Eve, the personal exoskeleton, the timeline is more specific. Wandercraft aims to commercialize Eve as early as 2026, with deployment intended for home and outdoor environments. This is a significant product category shift — moving from clinical rehabilitation settings to personal use — and it raises questions that the source material does not answer. The source does not disclose the expected price point for Eve, the training requirements for users, the warranty terms, or the service and maintenance infrastructure that will support home users. Buyers considering Eve should be aware that these details have not been publicly disclosed as of the funding announcement.
The Calvin-40 humanoid is described as an industrial-grade robot capable of performing physically demanding tasks. Renault Group is the first commercial partner and customer. The robot's name references its development time of 40 days, and it is integrated with NVIDIA's Isaac technologies. For industrial operators, the key question is whether Calvin-40 is commercially available beyond Renault. The source material does not specify a general availability date, pricing, or the specific tasks the robot can perform. The claim that it can handle "physically demanding tasks" is broad and does not include performance specifications, payload capacities, or operational parameters.
One notable detail is that the source material does not provide any information about service and support infrastructure for any of Wandercraft's products. There are no disclosed service level agreements, response times, spare-part lead times, or maintenance schedules. Buyers and operators should treat these as unknown factors and seek clarification directly from Wandercraft before making procurement decisions.
Similarly, the source material does not disclose the total number of Atalante X units deployed, the number of patients who have used the system, or clinical outcome data from real-world use. While the FDA clearance is a meaningful regulatory milestone, it does not by itself provide the kind of operational data that procurement teams typically want to review.
The funding itself — $75 million in Series D — provides some indication of the company's financial runway, but the source does not disclose how long the company expects this funding to last, what burn rate it anticipates, or what milestones it needs to hit before seeking additional capital. For buyers entering into long-term procurement agreements, understanding the financial stability of the supplier is relevant, and the source material offers only partial information on this front.
The Renault partnership is perhaps the most concrete signal for buyers. Renault's willingness to take a minority stake and commit as a customer suggests that the industrial applications of Wandercraft's technology have passed some level of due diligence by a major European manufacturer. However, the source does not disclose the terms of the partnership, the expected production volumes, or the timeline for scaling manufacturing.
For European buyers specifically, there is also the question of regulatory compliance. The source material confirms FDA clearance for Atalante X but does not mention CE marking or other European regulatory approvals. Given that Wandercraft is a French company, European regulatory compliance is presumably in place or in progress, but the source does not confirm this. Buyers should verify the regulatory status of each product in their specific jurisdiction before purchase.
Finally, the source material does not disclose any information about Wandercraft's service network, training programs, or customer support organization. For medical devices like exoskeletons, training for clinicians and patients is typically a critical component of successful adoption. For industrial robots, operator training and ongoing technical support are equally important. The absence of this information in the source material does not mean these services do not exist — it simply means they have not been publicly disclosed in the context of this funding announcement.
In summary, the $75 million Series D round positions Wandercraft for an ambitious expansion across three product lines, with Renault Group providing both capital and industrial expertise. The company reports strong revenue growth and has regulatory clearance for its rehabilitation system in the United States. However, for buyers and operators, several key details — pricing, service infrastructure, regulatory status in Europe, performance specifications for Calvin-40, and post-sale support — remain undisclosed. Procurement decisions should be based on direct engagement with the company and verification of these details.
Sources
Published by Vigla Media OÜ (Estonia).